Risk-Reward Balanced at Allos - Analyst Blog
May 20 2011 - 12:49PM
Zacks
We are maintaining our Neutral recommendation on Allos
Therapeutics Inc. (ALTH) with a target price of $2.50.
Allos, founded in 1992 and headquartered in Westminster,
Colorado, is a biopharmaceutical company focused on the development
and commercialization of small molecule drugs for the treatment of
cancer. The company, formerly known as HemoTech Sciences, Inc.,
changed its name to Allos Therapeutics, Inc. in October 1994.
Allos’ sole marketed product is Folotyn (pralatrexate), approved
for treating patients suffering from relapsed or refractory
peripheral T-cell lymphoma (PTCL). The drug received accelerated
approval from the US Food and Drug Administration (FDA) in
September 2009.
While the drug has been available to patients since October
2009, it was launched commercially in January 2010. Even though
Folotyn is currently the only FDA-approved drug for PTCL,
additional competition could come in the form of Celgene
Corporation’s (CELG) Istodax, which is under review in the
US for the same indication.
Folotyn is also being developed for other indications. The
company is leaving no stone unturned to make Folotyn a success. In
May 2011, Allos signed a co-development and commercialization deal
for Folotyn with Mundipharma International Corporation Ltd.
Per the terms of the deal, the sole responsibility of
commercializing the drug in the US and Canada lies with Allos.
Mundipharma is responsible for commercializing Folotyn in the rest
of the world.
Folotyn is also under review in Europe. If the drug is approved
in Europe then the original terms of the deal, which make Allos
responsible for funding 60% of Folotyn’s development costs, would
be modified to allow for equal sharing.
However, the dependence on one drug for growth concerns us. We
believe that Allos, which is characterized by the absence of a
decent pipeline, must develop additional products to sustain
growth. Consequently, we see limited upside potential from current
levels and retain our ‘Neutral’ view on Allos.
ALLOS THERAPEUT (ALTH): Free Stock Analysis Report
CELGENE CORP (CELG): Free Stock Analysis Report
Zacks Investment Research
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024